Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

(Reuters) - U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...

The U.S. Food and Drug Administration (FDA) has approved the fourth indication for AbbVie's (NYSE:ABBV) anti-wrinkle therapy ...

AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...

October 28, 202410:12 PM UTCUpdated ago Oct 28 (Reuters) - U.S. drugmaker AbbVie (ABBV.N), opens new tab said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an ...